Oncology Business Management | Specialty

FDA OKs Launch of Phase III Tocilizumab Trial for COVID-19 Pneumonia

March 23rd 2020

The FDA has approved the initiation of a double-blind, randomized phase III clinical trial of the oncology supportive care drug tocilizumab for use in combination with standard of care for the treatment of hospitalized adult patients with severe COVID-19 pneumonia.

ASCO Speaks Out on COVID-19

March 21st 2020

Experts from ASCO detail the organization's response to the COVID-19 crisis and resources available for its members.

COVID-19 Is "Biggest Medical Issue" of Modern Times, Rugo Says

March 20th 2020

The need to establish preventive procedures that keep pace with the rapid evolution of coronavirus 2019 presents numerous challenges for the oncology field as institutions adapt standard treatment protocols to minimize the risk for virus spread among clinicians and patients alike.

Dr. Brufsky on Case Ascertainment Bias With COVID-19

March 20th 2020

Adam M. Brufsky, MD, PhD, discusses case ascertainment bias regarding the coronavirus 2019.

Oncology Supportive Care Drug Explored as Treatment for COVID-19 Pneumonia

March 20th 2020

Tocilizumab, a treatment used for adverse events related to cancer therapy, among other indications, is being explored in a phase III trial as a treatment for adult patients hospitalized with severe COVID-19 pneumonia, according to Genentech (Roche), the manufacturer of the interleukin-6 receptor antagonist.

Oncology Fellowship Director Discusses His Recruitment Principles

March 19th 2020

Like all fellowship directors, Gerald Hsu, MD, PhD, is looking for applicants with intelligence, ambition, and a desire to advance cancer research and clinical care.

Oncology Organizations Issue Guidance for Coronavirus

March 19th 2020

Physicians treating patients with cancer may want to consider postponing surgeries or altering therapy plans because of the threat that the coronavirus poses to this population.

Dr. Borgen on Unanswered Questions With COVID-19

March 19th 2020

Patrick I. Borgen, MD, discusses what is currently known about coronavirus 2019 and unanswered questions that still need to be addressed.

Moving to Electronic Prior Authorization Requires Incremental Steps

March 18th 2020

In a time of tremendous technological advancement, how is it that 90% of communications between providers and payers for prior authorizations are still done by phone or fax, and how do we move to more automated processes?1

Cancer Registry Launches to Inform COVID19+ Patient Demographics

March 18th 2020

Jeremy L. Warner, MD, MS, discusses the goals of the COVID-19 and Cancer Consortium Registry, what other data need to be extrapolated with COVID-19, and how the virus could impact patients with cancer.

Dr. Campbell on Precautions for Preventing Spread of COVID-19

March 18th 2020

Matthew T. Campbell, MD, MS, shares ways to prevent the spread of coronavirus 2019.

Dr. Bardia on the Potential Impact of COVID-19 on Immunocompromised Patients

March 18th 2020

Aditya Bardia, MD, MPH, discusses the potential impact of novel coronavirus on immunocompromised patients.

Automated Prior Authorization Catches On

March 17th 2020

In January, America’s Health Insurance Plans in collaboration with payers representing 60 million covered individuals launched the Fast Prior Authorization Technology Highway to improve the prior authorization process.

The Future Direction of Biosimilars

March 16th 2020

The Availability of Multiple Biosimilars for 1 Biologic

March 16th 2020

Educating Physicians When Prescribing Biosimilars

March 16th 2020

Pharmacovigilance Requirements for Biosimilar Products

March 16th 2020

Biosimilar Interchangeability in Practice

March 16th 2020

Evidence-Based Extrapolation for Biosimilars

March 16th 2020

The Complexity of Choosing Biosimilars in Oncology

March 16th 2020